Could ozempic shield psoriatic arthritis patients from heart disease?
NCT ID NCT07251556
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether semaglutide (Ozempic), a drug used for diabetes and weight loss, can slow the buildup of plaque in arteries of people with psoriatic arthritis who do not have diabetes. Forty participants will receive either semaglutide or no additional treatment for 24 weeks. Researchers will measure changes in carotid artery thickness and stiffness to see if the drug reduces heart disease risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide (Ozempic)
- What this could lead to
- If it works, this could point toward a new way to lower heart disease risk in people with psoriatic arthritis who do not have diabetes.
- What could go wrong
- This is a small, early proof-of-concept study with only 40 participants, so results may not apply widely. The drug can cause gastrointestinal side effects, and it is not yet known if it will meaningfully affect artery health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting diet shows promise for psoriasis relief
- Costa rica psoriasis study reveals hidden heart and joint risks
- Costa rica launches registry to see how new psoriasis drugs work in real life
- New study tracks psoriatic arthritis treatment success across therapy lines
- Can Biomarker-Guided biologics tame psoriasis and arthritis?